Conestoga Capital Advisors buys $49,162,774 stake in Cantel Medical Corp. (CMN)

Cantel Medical Corp. (CMN) : Conestoga Capital Advisors scooped up 14,370 additional shares in Cantel Medical Corp. during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Oct 11, 2016. The investment management firm now holds a total of 622,550 shares of Cantel Medical Corp. which is valued at $49,162,774.Cantel Medical Corp. makes up approximately 3.38% of Conestoga Capital Advisors’s portfolio.

Other Hedge Funds, Including , Cutler Group Lp added CMN to its portfolio by purchasing 100 company shares during the most recent quarter which is valued at $7,897.First Mercantile Trust Co reduced its stake in CMN by selling 2,133 shares or 10.72% in the most recent quarter. The Hedge Fund company now holds 17,759 shares of CMN which is valued at $1,396,213. Cantel Medical Corp. makes up approx 0.19% of First Mercantile Trust Co’s portfolio.Bnp Paribas Arbitrage Sa reduced its stake in CMN by selling 5,689 shares or 50.67% in the most recent quarter. The Hedge Fund company now holds 5,539 shares of CMN which is valued at $434,590. Eqis Capital Management added CMN to its portfolio by purchasing 5,043 company shares during the most recent quarter which is valued at $395,674. Cantel Medical Corp. makes up approx 0.02% of Eqis Capital Management’s portfolio. Washington Trust Bank added CMN to its portfolio by purchasing 11 company shares during the most recent quarter which is valued at $863.

Cantel Medical Corp. closed down -2.32 points or -2.94% at $76.65 with 1,25,620 shares getting traded on Tuesday. Post opening the session at $78.97, the shares hit an intraday low of $76.33 and an intraday high of $78.97 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.

On the company’s financial health, Cantel Medical Corp. reported $0.48 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Sep 29, 2016. Analyst had a consensus of $0.45. The company had revenue of $179.00 million for the quarter, compared to analysts expectations of $178.58 million. The company’s revenue was up 18.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.39 EPS.

Many Wall Street Analysts have commented on Cantel Medical Corp.. Cantel Medical Corp. was Initiated by Needham to “Hold” on Aug 24, 2016.

Cantel Medical Corp. is a provider of infection prevention and control products and services in the healthcare market. The Company’s segments include Endoscopy Water Purification and Filtration Healthcare Disposables Dialysis and Specialty Packaging. Its Endoscopy segment includes medical device reprocessing systems disinfectants detergents and other supplies. The Company’s Water Purification and Filtration segment includes water purification equipment and services filtration and separation products and disinfectants sterilization and decontamination products and services. Its Healthcare Disposables segment includes single-use infection prevention and control healthcare products. The Company’s Dialysis segment includes medical device reprocessing systems sterilants/disinfectants and dialysate concentrates. Its Specialty Packaging segment includes specialty packaging and thermal control products as well as related compliance training.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Cantel Medical Corp. - Is it time to Sell?

Top Brokerage Firms are advising their investors on Cantel Medical Corp.. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.